TRPA1 and diabetic neuropathy: A phase 2a clinical study yielded data indicating that the TRPA1 antagonist, GRC 17536, alleviates pain with no other drug-related side effects in patients with painful diabetic neuropathy, which supports the promising therapeutic efficacy of TRPA1 blockade in pain management (Pharmaceuticals, 2014).